Pfizer (PFE) Tops Q2 EPS by 21c, Beats on Revenue; Offers FY25 EPS Guidance

Pfizer (NYSE: PFE) reported Q2 EPS of $0.78, $0.21 better than the analyst estimate of $0.57. Revenue for the quarter came in at $14.7 billion versus the consensus estimate of $13.47 billion.

GUIDANCE:

Pfizer sees FY2025 EPS of $2.90-$3.10, versus the consensus of $3.01.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Goldman Equities Haul To Rip Past $5 Billion Toward New Record - Bloomberg
• BMO Capital on Pfizer (PFE): 'SigVie Trial Misses on OS With Signs of Benefit for Future Trials'
• Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald on Negative SV Data